Oct.29 (Beijing)The 8th China Pharmaceutical Entrepreneurs Annual Meeting and 2016 Innovation Forum of Medicine Industry, which is sponsored by China Pharmaceutical Enterprises Management Association and organized by E Medicine Managers' Magazine, was held in Beijing. The Awarding Ceremony of the 8th Appraisal of Chinese Pharmaceutical Listed Company's Competitiveness was open during the conference. Tasly was listed in the Top 20 in terms of competitive power for the 8th time in successive eight Years, and at the same time selected in the list of Top 10 Companies with Most Investment Value.

Sponsored by China Medicine Enterprises Management Association, the appraisal of Top 20 of Most Competitive Pharmaceutical Listed Company in China, which has been held for eight years, is based on data of the companies in previous year including sales income, profit, total market value, sales growth, profit growth, market value growth, net assets income rate, asset-liability rate and currency ratio. Owing to its rationality for appraisal system, objectivity and justice of the selection process and strong impact for the result, it has won widely recognition and positive evaluation from the listed companies.

Having won the two prizes for successive eight years, Tasly is thereby proved to have excellent shareholders value creation ability and be a good target for domestic and overseas investors for long-term investment.

(Translated by Anna Si)

Tianjin Tasly Pharmaceutical Co. Ltd. published this content on 03 November 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 04 November 2016 16:07:05 UTC.

Original documenthttp://www.tasly.com/show.aspx?id=11751&cid=22

Public permalinkhttp://www.publicnow.com/view/1606165C0864449C1E81A7947FF73B9678A567FA